Tazemetostat

5 trials 2 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

4 Sponsors

8 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 1 Phase II: 1 Phase I/II: 2 Phase I (FiH): 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

Extraskeletal myxoid chondrosarcoma 1 Mesothelioma malignant recurrent 1 Mesothelioma 1 Follicle centre lymphoma follicular grade I II III 1 Synovial sarcoma 1 Follicle centre lymphoma diffuse small cell lymphoma 1 Non-Hodgkin's lymphoma 1

Sponsors using this IMP

Epizyme Inc. 2 Celgene Corp. 1 Institut Bergonie 1 LYSARC 1

All trials

5 total

Phase 1b/2a Study to Evaluate CC-92480 (BMS-986348) in Combination with Other Treatments in Relapsed or Refractory Multiple Myeloma Recruiting

2023-509384-25-00 Phase I/II 2 countries Celgene Corp.
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Phase III 7 countries Epizyme Inc.
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Phase I (FiH) 2 countries LYSARC
CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER Ended

2023-509501-72-00 Phase II 1 country Institut Bergonie
ROLLOVER STUDY FOR TAZEMETOSTAT Ended

2023-510553-41-00 Phase I/II 2 countries Epizyme Inc.

Showing 1–5 of 5 trials

← All drugs A–Z